Profile data is unavailable for this security.
About the company
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.
- Revenue in USD (TTM)7.10m
- Net income in USD-39.43m
- Incorporated2014
- Employees22.00
- LocationSpruce Biosciences Inc611 Gateway Boulevard, Suite 740SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 655-4168
- Fax+1 (302) 636-5454
- Websitehttps://sprucebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEI Pharma Inc | 0.00 | -46.60m | 18.52m | 28.00 | -- | 0.7446 | -- | -- | -6.99 | -6.99 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -72.25 | -21.09 | -79.28 | -23.99 | -- | -- | -- | -72.23 | -- | -- | 0.00 | -- | 33.76 | 67.75 | 155.84 | -- | -49.68 | -- |
| NanoViricides Inc | 0.00 | -9.45m | 18.69m | 7.00 | -- | 1.86 | -- | -- | -0.7579 | -0.7579 | 0.00 | 0.7188 | 0.00 | -- | -- | 0.00 | -69.61 | -43.88 | -76.92 | -46.26 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.43 | -- | 16.23 | -- |
| Palatin Technologies, Inc. | 2.38m | -32.35m | 18.77m | 30.00 | -- | -- | -- | 7.87 | -1.98 | -1.98 | 0.1434 | -0.3932 | 0.3252 | -- | -- | 79,470.34 | -441.31 | -55.28 | -- | -69.08 | 95.90 | -- | -1,357.06 | -1,359.14 | -- | -- | -- | -- | -7.49 | -40.52 | -23.71 | -- | 3.31 | -- |
| Unity Biotechnology Inc | 0.00 | -19.05m | 19.21m | 19.00 | -- | 1.36 | -- | -- | -1.14 | -1.14 | 0.00 | 0.8394 | 0.00 | -- | -- | 0.00 | -32.73 | -47.21 | -38.49 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 19.26m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 19.35m | 18.00 | -- | 1.36 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -11.24m | 19.51m | 3.00 | -- | 6.01 | -- | -- | -0.7287 | -0.7287 | 0.00 | 0.2197 | 0.00 | -- | -- | 0.00 | -169.22 | -- | -191.76 | -- | -- | -- | -- | -- | -- | -3.32 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Goldenwell Biotech Inc | 940.00 | -137.11k | 19.80m | -- | -- | 5,169.71 | -- | 21,063.83 | -0.0014 | -0.0014 | 0.00001 | 0.00004 | 0.0048 | 0.0031 | -- | -- | -69.82 | -- | -70.29 | -- | 42.55 | -- | -14,586.17 | -- | 21.43 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Spruce Biosciences Inc | 7.10m | -39.43m | 19.96m | 22.00 | -- | 0.3866 | -- | 2.81 | -0.9598 | -0.9598 | 0.1728 | 1.25 | 0.0798 | -- | -- | 244,862.10 | -44.28 | -41.24 | -55.51 | -46.49 | -- | -- | -555.23 | -1,774.39 | -- | -121.12 | 0.0399 | -- | -- | -- | -3.77 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -27.73m | 20.42m | 8.00 | -- | 1.58 | -- | -- | -4.77 | -4.77 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -114.20 | -95.57 | -159.68 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| GlycoMimetics Inc | 10.00k | -39.74m | 20.43m | 35.00 | -- | 1.80 | -- | 2,042.85 | -0.6165 | -0.6165 | 0.0002 | 0.1764 | 0.0003 | -- | 0.0836 | 285.71 | -115.34 | -43.60 | -136.58 | -47.82 | -- | -- | -397,350.50 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Kairos Pharma Ltd | 0.00 | -2.74m | 20.55m | -- | -- | 6.17 | -- | -- | -0.2279 | -0.2279 | 0.00 | 0.2594 | 0.00 | -- | -- | -- | -92.10 | -- | -264.70 | -- | -- | -- | -- | -- | -- | -2.61 | 0.0409 | -- | -- | -- | -72.57 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -350.57m | 20.95m | 5.00 | -- | -- | -- | -- | -9.61 | -9.61 | 0.00 | -0.8106 | 0.00 | -- | -- | 0.00 | -3,242.54 | -- | -- | -- | -- | -- | -- | -- | -- | 2.94 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.44m | 21.93m | 4.00 | -- | 8.50 | -- | -- | -1.09 | -1.09 | 0.00 | 0.1589 | 0.00 | -- | -- | 0.00 | -250.15 | -- | -498.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Spruce Biosciences Inc's reporting currency: US Dollar USD
16.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rock Springs Capital Management LPas of 30 Sep 2024 | 2.61m | 6.32% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 1.26m | 3.05% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 835.75k | 2.02% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 609.70k | 1.48% |
| Adar1 Capital Management LLCas of 30 Sep 2024 | 403.72k | 0.98% |
| Almitas Capital LLCas of 30 Sep 2024 | 396.51k | 0.96% |
| Geode Capital Management LLCas of 30 Sep 2024 | 261.95k | 0.63% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 124.73k | 0.30% |
| Citadel Securities LLCas of 30 Sep 2024 | 77.05k | 0.19% |
| Lion Point Capital LPas of 30 Sep 2024 | 75.00k | 0.18% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
